ONCOLOGY

Distress within 1 year before or after cancer diagnosis increases mortality.

NACT tied to lower morbidity, but no survival advantage in advanced disease.

Olaparib can be used within the Cancer Drugs Fund for BRCA-positive, advanced epithelial ovarian, fallopian tube or primary peritoneal cancer

Post hoc analysis of phase 3 PORTEC-3 trial.

Laparotomy for early-stage and fertility-sparing surgery for borderline are recommended.

Objective response rate was 88% in advanced/recurrent disease.

Recurrence risk also doubled vs open radical hysterectomy.

Estimates based on a modelling by the University of Warwick.

Integrated score of 6 proteins shows AUC of 0.80.

Resulting ICER is within the willingness-to-pay threshold in the Netherlands.

Bevacizumab-bvzr could offer a cheaper alternative to the reference product.

Incorporating cytoreductive surgery into the initial management of epithelial ovarian cancer improves survival

Study identifies which patients are most likely to benefit.

The meta-analysis shows greater and faster impact and herd effects in countries with both multi-cohort and high vaccination coverage.